Opioid antagonists are associated with a reduction in the symptoms of schizophrenia: a meta-analysis of controlled trials.

Clark, Samuel D; Van Snellenberg, Jared X; Lawson, Jacqueline M; Abi-Dargham, Anissa

Clark, Samuel D; Van Snellenberg, Jared X; Lawson, Jacqueline M; Abi-Dargham, Anissa.

Afiliação

Clark SD; Columbia University Medical Center, New York, NY, USA. Samclark1@gmail.com.
Van Snellenberg JX; Terran Biosciences, New York, NY, USA. Samclark1@gmail.com.
Lawson JM; Department of Psychiatry and Behavioral Health, Stony Brook University Medical Center, New York, NY, USA.
Abi-Dargham A; Department of Psychology, Stony Brook University, New York, NY, USA.

Neuropsychopharmacology ; 45(11): 1860-1869, 2020 10.

Article em En | MEDLINE | ID: mdl-32516800

Assuntos

Buprenorfina; Esquizofrenia; Buprenorfina/uso terapêutico; Humanos; Naloxona/uso terapêutico; Antagonistas de Entorpecentes/uso terapêutico; Esquizofrenia/tratamento farmacológico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esquizofrenia / Buprenorfina Tipo de estudo: Clinical_trials / Diagnostic_studies / Guideline / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google